PMID- 8780022
OWN - NLM
STAT- MEDLINE
DCOM- 19970114
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 66
IP  - 5
DP  - 1996 May
TI  - Effects of glutamate antagonists on methamphetamine and 
      3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo.
PG  - 1949-58
AB  - Several amphetamine analogues are reported to increase striatal glutamate efflux 
      in vivo, whereas other data indicate that glutamate is capable of stimulating the 
      efflux of dopamine (DA) in the striatum via a glutamate receptor-dependent 
      mechanism. Based on these findings, it has been proposed that the ability of 
      glutamate receptor-blocking drugs to antagonize the effects of amphetamine may be 
      explained by their capacity to inhibit DA release induced by glutamate. To 
      examine this possibility further, we investigated in vivo the ability of 
      glutamate antagonists to inhibit DA release induced by either methamphetamine 
      (METH) or 3,4-methylenedioxymethamphetamine (MDMA). Both METH and MDMA increased 
      DA efflux in the rat striatum and, in animals killed 1 week later, induced 
      persistent depletions of DA and serotonin in tissue. Pretreatment with MK-801 or 
      CGS 19755 blocked the neurotoxic effects of METH and MDMA but did not 
      significantly alter striatal DA efflux induced by either stimulant. Infusion of 
      6-cyano-7-nitro-quinoxaline-2,3-dione into the striatum likewise did not alter 
      METH-induced DA overflow, and none of the glutamatergic antagonists affected the 
      basal release of DA when given alone. The findings suggest that the 
      neuroprotective effects of NMDA antagonists do not involve an inhibition of DA 
      release, nor do the data support the proposal that glutamate tonically stimulates 
      striatal DA efflux in vivo. Whether phasic increases in glutamate content might 
      stimulate DA release, however, remains to be determined.
FAU - Finnegan, K T
AU  - Finnegan KT
AD  - Psychiatry Service, Veterans Administration Medical Center, Salt Lake City, Utah 
      84148, USA.
FAU - Taraska, T
AU  - Taraska T
LA  - eng
GR  - DA07239/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Amines)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Pipecolic Acids)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4VGJ4A41L2 (selfotel)
RN  - 6LR8C1B66Q (Dizocilpine Maleate)
RN  - 6OTE87SCCW (6-Cyano-7-nitroquinoxaline-2,3-dione)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology
MH  - Amines/antagonists & inhibitors
MH  - Animals
MH  - Corpus Striatum/*metabolism
MH  - Dizocilpine Maleate/pharmacology
MH  - Dopamine/*metabolism
MH  - *Excitatory Amino Acid Antagonists/pharmacology
MH  - Male
MH  - Methamphetamine/*pharmacology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Pipecolic Acids/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
AID - 10.1046/j.1471-4159.1996.66051949.x [doi]
PST - ppublish
SO  - J Neurochem. 1996 May;66(5):1949-58. doi: 10.1046/j.1471-4159.1996.66051949.x.